Clinical Oncology Next Generation Sequencing Market Size, Share, Trends, Growth and Forecast 2030

Clinical Oncology Next Generation Sequencing Industry Prospective:

The global clinical oncology next-generation sequencing market size was evaluated at $1100 million in 2022 and is slated to hit $8100 million by the end of 2030 with a CAGR of nearly 16% between 2023 and 2030.

Request Free Sample

Clinical Oncology Next Generation Sequencing Market: Overview

With genomics-focused pharmacology beginning to play a major role in cancer therapy, clinical next-generation sequencing (NGS) is emerging as a valuable method for obtaining an in-depth and accurate look into individual tumor molecular backgrounds. Furthermore, tailored therapies are rapidly emerging as the latest oncology standards of healthcare treatments. In addition to this, clinical NGS-driven companion diagnostics are widely viewed as enhanced treatment alternatives for improving patient outcomes in the near future.

Key Insights

• As per the analysis shared by our research analyst, the global clinical oncology next generation sequencing market is projected to expand annually at the annual growth rate of around 16% over the forecast timespan (2023-2030)
• In terms of revenue, the global clinical oncology next generation sequencing market size was evaluated at nearly $1100 million in 2022 and is expected to reach $8100 million by 2030.
• The global clinical oncology next generation sequencing market is anticipated to grow rapidly over the forecast timeline owing to a surge in healthcare spending.
• In terms of technology, the targeted sequencing & re-sequencing segment is slated to register the highest CAGR over the analysis period.
• Based on workflow, the NGS sequencing segment is expected to dominate the segmental growth over the assessment timeline.
• Based on application, the screening segment is expected to grow rapidly over the years ahead.
• Region-wise, the Asia-Pacific clinical oncology next generation sequencing industry is projected to register the fastest CAGR during the assessment timeline.

Request Free Sample

Clinical Oncology Next Generation Sequencing Market: Growth Factors

Surge in healthcare spending will steer the global market surge over the forecast period

Technological innovations and a rise in healthcare expenditure will prop up the expansion of the clinical oncology next generation sequencing market across the globe. Increase in cancer incidences across the globe will pave the way for a humungous surge in the global market in the years ahead. In addition to this, increasing use of next-generation sequencing for developing personalized medicine for treating cancer will prompt the expansion of the market globally. Additionally, surging acceptance of companion diagnostics will proliferate the size of the global market. Furthermore, a prominent increase in the use of next generation sequencing techniques for liquid biopsy will embellish the global market trends. Launching of new technologies is likely to contribute sizably towards the surge in the earnings of the global market. For instance, in the second half of 2022, Thermo Fisher Scientific Corporation introduced next-generation sequencing analysis and test software referred to as CE-IVD for enabling precision oncology testing of biomolecules. These initiatives are likely to spearhead the growth of the market globally.

Clinical Oncology Next Generation Sequencing Market: Restraints

Massive costs related to NGS systems can put brakes on the global industry expansion by 2030

High expenditure associated with clinical oncology next generation sequencing processes will curtail the growth of the clinical oncology next generation sequencing industry across the globe.

Clinical Oncology Next Generation Sequencing Market: Opportunities

Reduced prices of NGS systems can help market explore new domains of growth globally

Low costs of NGS tools and the introduction of new clinical oncology techniques by market players will open new growth panoramas for the global clinical oncology next generation sequencing market. Supportive government policies will prompt the expansion of the global market in the upcoming years.

Clinical Oncology Next Generation Sequencing Market: Challenges

Escalating costs of deploying NGS tools can prove to be a huge challenge for the global industry

Rise in the cost of installing the NGS systems and the restricted availability of sequencing tools in certain countries can prove to be a huge challenge for the global clinical oncology next generation sequencing industry.

Clinical Oncology Next Generation Sequencing Market: Segmentation

The global clinical oncology next generation sequencing market is sectored into technology, workflow, application, end-user, and region.                

In technology terms, the global clinical oncology next generation sequencing market is segregated into whole genome sequencing, whole exome sequencing, and targeted sequencing & re-sequencing segments. Furthermore, the targeted sequencing & re-sequencing segment, which acquired the highest share of the global market in 2022, is predicted to record the highest growth rate yearly in the upcoming years. The expansion of the segment in the forecasting period can be due to a rise in benefits offered by the targeted sequencing & re-sequencing technology that includes reduced costs, less time, and a rise in the quantity of data examined.

Based on the workflow, the global clinical oncology next generation sequencing industry is sectored into NGS pre-sequencing, NGS sequencing, and NGS data analysis segments. Moreover, the NGS sequencing segment, which amassed a key chunk of the global industry share in 2022, is expected to dominate the global industry over the analysis timeframe. The segmental expansion over the predicted timeline can be subject to the increase in the oncology sequencing projects.

Based on the application, the clinical oncology next generation sequencing market across the globe is divided into companion diagnostics, screening, and others segments. Among the application segment, the screening segment is projected to expand rapidly due to an increase in the use of NGS tools in cancer screening projects globally.

Based on the end-user, the clinical oncology next generation sequencing industry globally is divided into hospitals, clinics, laboratories, and others.

Clinical Oncology Next Generation Sequencing Market: Report Scope

Clinical Oncology Next Generation Sequencing Market: Regional Insights

North America is prognosis to maintain leadership position in the global clinical oncology next generation sequencing market in the forecasting years

North America, which accounted for 49% of the global clinical oncology next generation sequencing market revenue in 2022, will be a dominating region over the assessment timeline. Furthermore, the regional market expansion can be due to strict measures taken by regulatory authorities pertaining to cancer screening diagnosis in countries such as the U.S. Rise in fund allocation for research activities and the huge presence of key players in the sub-continent will drive the regional market trends.

Furthermore, Asia-Pacific clinical oncology next generation sequencing industry is set to register the fastest CAGR in the upcoming years owing to low costs of sequencing and supportive government guidelines. High investments by manufacturers will further add to the regional market growth in the coming years.

Clinical Oncology Next Generation Sequencing Market: Competitive Space

The global clinical oncology next generation sequencing market profiles key players such as:

• Agilent
• Beijing Genomics Institute (BGI)
• Qiagen NV
• Oxford Nanopore Technologies Ltd.
• Caris Life Sciences
• Eurofins Scientific
• Perkin Elmer Inc.
• Foundation Medicine
• Myriad Genetics
• Partek Inc.
• Pacific Bioscience Inc.
• Paradigm Diagnostics Inc.
• Thermo Fisher Scientific Corporation

The global clinical oncology next generation sequencing market is segmented as follows:

By Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Re-Sequencing

By Workflow

• NGS Pre-Sequencing
• NGS Sequencing
• NGS Data Analysis

By Application

• Screening
• Companion Diagnostics
• Others

By End-User

• Hospitals
• Clinics
• Laboratories
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa